title: Experimental model of equine alveolar macrophage stimulation with TLR ligands.
abstract: Pulmonary diseases are common in horses and have a major economic impact on the equine industry. Some of them could be associated with an inadequate immune response in the lung, but methods to evaluate this response in horses are lacking. The aim of this study was to develop and validate an experimental model that could be applied in several physiological and pathological conditions to assess the innate immune response of equine pulmonary cells. Equine alveolar macrophages (AMs) obtained from bronchoalveolar lavages were isolated from other cells by adhesion. TLR2, 3, and 4 expression in AMs was studied and their responses to commercial ligands (respectively FSL-1, Poly(I:C), and LPS) were evaluated after determination of the appropriate dose and time of incubation. TLR responses were assessed by measuring cytokine production using (1) gene expression of TNFα, IFNβ, Il-1β, and IFNα by qPCR (indirect method); and (2) cytokine production for TNFα and IFNβ by ELISA (direct method). TLR 2, 3, and 4 were expressed by AMs. TLR 2 stimulation with 10 ng/mL of FSL-1 during 3h significantly increased IL-1β and TNFα gene expression. TLR 3 stimulation with 1000 ng/mL of Poly(I:C) during 1h increased IFNβ, IFNα, Il-1β and TNFα expression. TLR 4 stimulation with 100 ng/mL of LPS during 3h increased TNFα, IFNβ, and Il-1β expression. Results obtained by ELISA quantification of TNFα and IFNβ produced by AMs following stimulation during 6h were similar: FSL-1 increased TNFα production but not IFNβ, Poly(I:C) and LPS increased production of IFNβ and TNFα. In conclusion, pulmonary innate immunity of horses can be assessed ex vivo by measuring cytokine production following stimulation of AMs with TLR agonists. This experimental model could be applied under several conditions especially to improve the understanding of equine respiratory disease pathogenesis, and to suggest novel therapeutic opportunities.
authors.affiliation: CIRALE-National Veterinary School of Alfort, Goustranville, France. ingrid.waldschmidt@hotmail.fr
authors.forename: Ingrid
authors.initials: I
authors.lastname: Waldschmidt
authors.forename: Dimitri
authors.initials: D
authors.lastname: Pirottin
authors.forename: Tatiana
authors.initials: T
authors.lastname: Art
authors.forename: Fabrice
authors.initials: F
authors.lastname: Audigié
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bureau
authors.forename: Irene
authors.initials: I
authors.lastname: Tosi
authors.forename: Sophie
authors.initials: S
authors.lastname: El Abbas
authors.forename: Frédéric
authors.initials: F
authors.lastname: Farnir
authors.forename: Eric
authors.initials: E
authors.lastname: Richard
authors.forename: Mari-Capucine
authors.initials: MC
authors.lastname: Dupuis
mesh_terms: D000818:Animals; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D015870:Gene Expression; D006736:Horses / Q000235:genetics / Q000276:immunology*; D007113:Immunity, Innate / Q000235:genetics; D016898:Interferon-alpha / Q000235:genetics; D016899:Interferon-beta / Q000096:biosynthesis / Q000235:genetics; D053583:Interleukin-1beta / Q000235:genetics; D008024:Ligands; D016676:Macrophages, Alveolar / Q000276:immunology* / Q000378:metabolism; D018448:Models, Immunological; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D051196:Toll-Like Receptor 3 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D051193:Toll-Like Receptors / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics
chemical_list: D016207:Cytokines; D016898:Interferon-alpha; D053583:Interleukin-1beta; D008024:Ligands; D012333:RNA, Messenger; D051195:Toll-Like Receptor 2; D051196:Toll-Like Receptor 3; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha; D016899:Interferon-beta
keywords: Alveolar macrophages; Cytokines; Horse; Innate immunity; mRNA